glp-1 news oct 21 2025 october What's next for GLP-1 innovation: A primer on the race reshaping pharma and chronic disease care GLP-1 Trends

After a review of the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators, Pfizer decided to discontinue development of the molecule

DSIP exhibits an unusual property among neuropeptides in that it appears relatively stable in plasma despite its small size, a characteristic researchers have attributed to possible circulating binding proteins

Neither NICE nor the NHS recommends L-carnitine supplementation as part of any weight management pathway, and no authorised health claims for weight loss exist on the GB Nutrition and Health Claims Register

M., Tam, S

Relax in our state-of-the-art clinic while you rejuvenate